The acquisition adds speculative pipeline value but no near-term revenue. Monitor for the GLS financial statements amendment (due ~Dec 15, 2026) and any FDA communication on GV104's NDA pathway.
Price Chart
Executive Summary
Hepion Pharmaceuticals completed the acquisition of Gravitas Life Sciences (GLS), a clinical-stage biotech developing opioid-overdose prophylaxis (GV104) and oral infliximab (GV023), for $2M cash + 25M shares (valued at ~$2.25M) plus $135K additional cash. The deal is a related-party transaction with multiple overlapping directors/officers. Concurrently, the company appointed GLS's former CEO as its new CEO and its interim CEO as CFO. The acquisition adds early-stage pipeline assets but no revenue, while the stock consideration creates dilution.
Key Financial Metrics
Key Facts
- Hepion acquired all membership interests of Gravitas Life Sciences (GLS) for $2,000,000 cash + 25,000,000 shares of common stock (valued at ~$2,250,000) + $135,000 additional cash.
- The transaction is a related-party deal: Vincent LoPriore, Gary Stetz, Sireesh Appajosyula and Chase LoPriore are directors of Hepion and officers/shareholders of GLS/Gravitas Collective.
- Gary Stetz appointed CFO (effective Oct 9, 2026); Sireesh Appajosyula appointed CEO (effective Oct 9, 2026).
- GLS is a pre-revenue clinical-stage biotech with two pipeline assets: GV104 (nalmefene buccal film for opioid prophylaxis, IND approved, NDA expected after CMC work in 2027) and GV023 (oral infliximab, preclinical).
- The 25M shares issued represent approximately 19.99% of Hepion's outstanding shares post-issuance (capped by agreement).
- Shares are subject to a 6-month lock-up and piggyback registration rights.
- Hepion assumed the Canton Seller Note obligations, paying $1,000,000 to Canton at closing.
- Financial statements of GLS required by Item 9.01 will be filed by amendment within 71 days.
Financial Impact
Total consideration ~$4.385M ($2M cash + ~$2.25M stock + $135K additional cash). Dilution of ~19.99% of outstanding shares. Hepion also assumed the Canton Seller Note (remaining balance undisclosed).
Risk Factors
- Pre-revenue pipeline with no approved products; GV104 NDA filing not expected until after 2027 CMC work.
- Significant dilution (~20%) from stock consideration.
- Related-party transaction raises governance concerns; overlapping directors may create conflicts.
- Hepion assumed the Canton Seller Note, adding debt to the balance sheet.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-046546 |
| Document: form8-k.htm | 0001493152-26-046546 |
| Document: 0001493152-26-046546-index-headers.html | 0001493152-26-046546 |
| Document: 0001493152-26-046546-index.html | 0001493152-26-046546 |
| Document: 0001493152-26-046546.txt | 0001493152-26-046546 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | SC 13D | $0.1310 | awaiting T+20 | — | $0.1201 (−8.32%) |
Oct 21, 2026 5d ago | SC 13G/A | $0.1350 | awaiting T+20 | — | $0.1201 (−11.04%) |
Oct 9, 2026 17d ago | 8-K | $0.1240 | awaiting T+20 | — | $0.1201 (−3.15%) |
Sep 28, 2026 29d ago | 8-K | $0.0800 $0.1281 | ▼ −60.13% | ▼ −60.16% | $0.1201 (−50.12%) |
Aug 12, 2026 10w ago | Insider Cluster | $0.0700 $0.0550 | ▼ −21.43% | ▼ −19.68% | $0.1201 (+71.57%) |
Apr 21, 2026 27w ago | Insider Cluster | $0.0700 $0.0750 | ▲ +7.14% | ▲ +1.67% | $0.1201 (+71.57%) |
Apr 21, 2026 27w ago | Insider Cluster | $0.0620 $0.0750 | ▲ +20.97% | ▲ +16.01% | $0.1201 (+93.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers